$The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma$

The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma

PIM447, a novel pan-PIM inhibitor, has shown preclinical activity in multiple myeloma (MM). In the multicenter, open-label, first-in-human study, patients with relapsed and/or refractory MM were enrolled to determine the maximum-tolerated dose (MTD) or recommended dose (RD), safety, pharmacokinetics...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2019-12, Vol.33 (12), p.2924-2933
Hauptverfasser:	Raab, Marc S., Thomas, Sheeba K., Ocio, Enrique M., Guenther, Andreas, Goh, Yeow-Tee, Talpaz, Moshe, Hohmann, Nicolas, Zhao, Sylvia, Xiang, Fang, Simon, Carl, Vanasse, K. Gary, Kumar, Shaji K.
Format:	Artikel
Sprache:	eng
Schlagworte:	38/23 631/67 692/699/1541/1990/804 Adult Aged Aged, 80 and over Anticancer properties Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Antitumor activity Cancer Research Critical Care Medicine Disease control Diseases Drug Monitoring Drug Resistance Enzyme inhibitors Female Health aspects Hematology Humans Inhibitors Intensive Internal Medicine Kinases Leukemia Male Medical research Medicine Medicine & Public Health Medicine, Experimental Middle Aged Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - metabolism Multiple Myeloma - pathology Oncology Patients Pharmacokinetics Population studies Powder injection molding Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - pharmacokinetics Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins c-pim-1 - antagonists & inhibitors Recurrence Relapse Toxicity Treatment Outcome Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!